N/A N=667 Randomized Screening

Feasibility and Acceptability of Offering Self-sampling to Non-attendees in Primary Care

Cancer of the Uterine Cervix

Bottom Line

View on ClinicalTrials.gov: NCT02698423 ↗

Enrolled (actual)

667

Serious AEs

—

Results posted

Jul 2017

Primary outcome: Primary: Number of Participants Who Performed HPV Self-testing Compared to the Number of Participants Who Responded to the Invitation to Come to the Hospital for Pap Testing — 317; 307 Participants

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: Cobas HPV DNA Test (Device); Papanicolau test (Other)
Age: Adult, Older Adult · 25+ yrs
Sex: Female
Sponsor: University Hospital, Geneva
Primary completion: Jan 2016

Outcome Measures

Outcome	Result	p-value
PRIMARY Number of Participants Who Performed HPV Self-testing Compared to the Number of Participants Who Responded to the Invitation to Come to the Hospital for Pap Testing	317; 307	—
SECONDARY Proportion of Women With a Positive HPV Self-test Who Underwent All the Recommended Follow-up Clinical Investigations.	317; 307	—

Summary

The purpose of this study is to determine whether human-papillomavirus (HPV) self-sampling can be used as a primary screening test for unscreened women.

Eligibility Criteria

Inclusion Criteria

No previous cervical cancer screening test in the last three years

Exclusion Criteria

pregnancy
previous hysterectomy

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02698423). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.